Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience

Tiwana, Manpreet S.; Lee, Hsueh Ni; Saini, Sunil; Verma, Suman; Gupta, Meenu; Gupta, Madhur; Jain, Neha; Sindhwani, Girish; Rawat, Jagdish; Saini, Manju; Chauhan, Neena; Gaur, Dushyant Singh

doi:10.4103/0970-2113.116250

Cited by 10 publications

(6 citation statements)

References 25 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On a multivariate analysis, they found that delivery of a higher biologically equivalent radiotherapy dose (BED) correlated with better OS in patients with Stage III disease; in the Stage IV patients, nonsquamous histology, administration of chemotherapy, PR to chemotherapy, presence of skeletal metastases, and a higher BED significantly correlated with a better OS. [ 33 ]…”

Section: Therapy Of Lung Cancermentioning

confidence: 99%

Lung cancer in the Indian subcontinent

Noronha

Pinninti

Patil

et al. 2016

South Asian J Cancer

View full text Add to dashboard Cite

Smoking tobacco, both cigarettes and beedis, is the principal risk factor for causation of lung cancer in Indian men; however, among Indian women, the association with smoking is not strong, suggesting that there could be other risk factors besides smoking. Despite numerous advances in recent years in terms of diagnostic methods, molecular changes, and therapeutic interventions, the outcomes of the lung cancer patients remain poor; hence, a better understanding of the risk factors may impact the preventive measures to be implemented at the community level. There is a lack of comprehensive data on lung cancer in India. In this review, we attempt to collate the available data on lung cancer from India.

show abstract

Section: Therapy Of Lung Cancermentioning

confidence: 99%

Lung cancer in the Indian subcontinent

Noronha

Pinninti

Patil

et al. 2016

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…For patients with unresectable stage III disease, definitive cCRT (platinum-based doublet regimens), followed by durvalumab consolidation is recommended as a treatment option in patients who have not progressed after definitive cCRT ( 9 ). The treatment practices within Asia vary from country to country such as induction CT followed by radiotherapy (RT) in India (stage III/IV), surgery or neoadjuvant therapy or definitive chemoradiotherapy (CRT) in Korea (stage III) and cCRT in Singapore (stage III) ( 10 – 12 ). With a high prevalence of epidermal growth factor receptor mutations (EGFRm) in China (46.5%, 309/665), CT was followed by tyrosine kinase inhibitors (TKIs) in most (66.3%, 205/309) patients with unresectable stage IIIB/IV ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset

et al. 2023

View full text Add to dashboard Cite

IntroductionStage III non-small cell lung cancer (NSCLC) is a heterogeneous disease requiring multimodal treatment approaches. KINDLE-Asia, as part of a real world global study, evaluated treatment patterns and associated survival outcomes in stage III NSCLC in Asia.MethodsRetrospective data from 57 centers in patients with stage III NSCLC diagnosed between January 2013 and December 2017 were analyzed. Median progression free survival (mPFS) and median overall survival (mOS) estimates with two sided 95% confidence interval (CI) were determined by applying the Kaplan-Meier survival analysis.ResultsOf the total 1874 patients (median age: 63.0 years [24 to 92]) enrolled in the Asia subset, 74.8% were men, 54.7% had stage IIIA disease, 55.7% had adenocarcinoma, 34.3% had epidermal growth factor receptor mutations (EGFRm) and 50.3% had programmed death-ligand 1 (PD-L1) expression (i.e. PD-L1 ≥1%). Of the 31 treatment approaches as initial therapy, concurrent chemoradiotherapy (CRT) was the most frequent (29.3%), followed by chemotherapy (14.8%), sequential CRT (9.5%), and radiotherapy (8.5%). Targeted therapy alone was used in 81 patients of the overall population. For the Asia cohort, the mPFS and mOS were 12.8 months (95% CI, 12.2–13.7) and 42.3 months (95% CI, 38.1–46.8), respectively. Stage IIIA disease, Eastern Cooperative Oncology Group ≤1, age ≤65 years, adenocarcinoma histology and surgery/concurrent CRT as initial therapy correlated with better mOS (p < 0.05).ConclusionsThe results demonstrate diverse treatment patterns and survival outcomes in the Asian region. The high prevalence of EGFRm and PD-L1 expression in stage III NSCLC in Asia suggests the need for expanding access to molecular testing for guiding treatment strategies with tyrosine kinase inhibitors and immunotherapies in this region.

show abstract

“…[ 21 ] Previously, it has been shown that a significant proportion of patients with lung cancer have an advanced stage of disease at presentation (Stage 3B and 4). [ 22 ] One of the potential reasons could be increased availability and practice of performing baseline PET scan. [ 23 ] A large database study involving more than 30000 patients reported a higher proportion of males with advanced stage lung cancer as compared with females, a finding that is contrary to the current study.…”

Section: Discussionmentioning

confidence: 99%

Lung cancer in Asian Indian females: Identification of disease-specific characteristics and outcome measures over a 12-year period

Mohan

Iyer²,

Ghosh³

et al. 2023

Lung India

View full text Add to dashboard Cite

Aim: Globally, the incidence of lung cancer amongst women appears to be increasing. We aimed to compare the socio-epidemiological and clinical characteristics of lung cancer amongst men and women from a large cohort at a tertiary care hospital in Northern India. Methods: Records of patients diagnosed with lung cancer between January 2008 and March 2020 were reviewed. Baseline epidemiological data, clinical characteristics, histologic profiles, treatment administered, and survival were compared between males and females. Results: A total of 2054 male and 438 female patients were included in analysis. Compared to males, female patients were younger [median age, 56 vs. 60 years, P < 0.001)], less likely to be working, less educated beyond secondary level and less likely to be smokers (29.1% vs. 84.9%, P < 0.0001). No difference in baseline performance status was observed. Females were more frequently diagnosed with adenocarcinoma (54.2% vs. 30.2%, P = <0.0001), stage IV disease (70.8% vs. 63%, P = 0.001), and had higher rate of EGFR mutation (37.2% vs. 21.5%, P < 0.0001). There was no difference in the proportion of females receiving cancer-specific therapy. Multivariate Cox proportional hazards model revealed higher progression-free survival [median 9.17 vs. 7.23 months; P = 0.007] and overall survival [median 13.80 vs. 9.10 months respectively, P = 0.001] amongst females compared to males. Conclusion: Amongst a large cohort of lung cancer, females demonstrated several distinct and characteristic demographics as well as disease-related features, especially better survival outcomes.

show abstract

Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience

Cited by 10 publications

References 25 publications

Lung cancer in the Indian subcontinent

Lung cancer in the Indian subcontinent

Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset

Lung cancer in Asian Indian females: Identification of disease-specific characteristics and outcome measures over a 12-year period

Contact Info

Product

Resources

About